<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00731276</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000601207</org_study_id>
    <secondary_id>SINGAPORE-NCC0703</secondary_id>
    <nct_id>NCT00731276</nct_id>
  </id_info>
  <brief_title>Irinotecan in Treating Asian Patients With Solid Tumors</brief_title>
  <official_title>Phase I Study to Investigate Genotype-based Dose Individualization of Irinotecan in Asian Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Centre, Singapore</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Centre, Singapore</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as irinotecan, work in different ways to stop the&#xD;
      growth of tumor cells, either by killing the cells or by stopping them from dividing.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of irinotecan in&#xD;
      treating Asian patients with solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To determine the dose-limiting toxicity and maximum tolerated dose of irinotecan&#xD;
           hydrochloride according to the genotype status of Asian patients with solid tumors.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To investigate the pharmacokinetics of irinotecan hydrochloride and its metabolites&#xD;
           SN-38 and SN-38G.&#xD;
&#xD;
        -  To evaluate time to tumor response, response duration, and time to progression in these&#xD;
           patients.&#xD;
&#xD;
      OUTLINE: Patients are stratified according to genotype status (UGT1A1*28 vs UGT1A1*6)&#xD;
&#xD;
      Patients receive irinotecan hydrochloride IV once weekly for 3 weeks. Treatment repeats every&#xD;
      4 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Patients undergo blood sample collection periodically for pharmacogenetic, pharmacokinetic,&#xD;
      and pharmacodynamic studies.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 3, 2008</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose-limiting toxicity</measure>
    <time_frame>No time frame defined. Trial is still recruiting.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum tolerated dose</measure>
    <time_frame>No time frame defined. Trial is still recruiting.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics</measure>
    <time_frame>No time frame defined. Trial is still recruiting.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to tumor response</measure>
    <time_frame>No time frame defined. Trial is still recruiting.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
    <time_frame>No time frame defined. Trial is still recruiting.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response duration</measure>
    <time_frame>No time frame defined. Trial is still recruiting.</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <arm_group>
    <arm_group_label>Four Regimens</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The study has four type of regimens, and dosing of irinotecan depends on genotype of patient.&#xD;
Four Regimens are:&#xD;
Weekly Irinotecan (Irinotecan given at day 1, 8 and 15) every four weekly&#xD;
Weekly Xeliri ( Irinotecan given at day 1, 8 and 15)+ (Xeloda tabs 2000mg/m2 consumed over 14 days) every three weekly&#xD;
Three-weekly Xeliri (Irinotecan given at day 1 only) + (Xeloda tabs 2000mg/m2 consumed over 14 days) every three weekly&#xD;
Two-weekly FOLFIRI (Irinotecan given at day 1 only) + (CI Fluorouracil 600mg/m2 over 22hrs, IV Folinic Acid 200mg/m2 over 2hrs and IVP Fluorouracil 400mg/m2) every two weekly</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>irinotecan hydrochloride</intervention_name>
    <arm_group_label>Four Regimens</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacogenomic studies</intervention_name>
    <arm_group_label>Four Regimens</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
    <arm_group_label>Four Regimens</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed solid tumors&#xD;
&#xD;
               -  Failed at least one line of prior chemotherapy&#xD;
&#xD;
          -  Must belong to either Chinese, Malay, or Indian ethnic groups&#xD;
&#xD;
          -  Previously irradiated disease allowed provided marker lesions not within the&#xD;
             irradiated field&#xD;
&#xD;
          -  Presence of at least one bidimensionally measurable, non-CNS indicator lesion, defined&#xD;
             by radiologic study (including CT or MRI scan, ultrasound, or chest X-ray) or physical&#xD;
             exam, meeting 1 of the following criteria:&#xD;
&#xD;
               -  Measurable disease on CT or MRI scan must have one diameter ≥ 1 cm and one&#xD;
                  diameter ≥ 2 cm&#xD;
&#xD;
               -  Measurable disease on chest X-ray or ultrasound must have both diameters ≥ 2 cm&#xD;
&#xD;
               -  Palpable tumor masses that cannot be evaluated radiologically must have two&#xD;
                  diameters ≥ 2 cm&#xD;
&#xD;
               -  Measurable skin lesion must have at least one diameter ≥ 1 cm&#xD;
&#xD;
          -  No unidimensionally measurable or evaluable only disease&#xD;
&#xD;
          -  No known brain or leptomeningeal metastasis&#xD;
&#xD;
          -  No uncontrolled large pleural effusions&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  Life expectancy ≥ 3 months&#xD;
&#xD;
          -  Absolute granulocyte count ≥ 1,000/µL&#xD;
&#xD;
          -  WBC ≥ 3,500/µL&#xD;
&#xD;
          -  Hemoglobin ≥ 9 g/dL&#xD;
&#xD;
          -  Platelet count ≥ 100,000/µL&#xD;
&#xD;
          -  Serum total bilirubin ≤ 2.0 mg/dL&#xD;
&#xD;
          -  ALT/AST &lt; 2.5 times normal (5 times normal in patients with known metastatic disease&#xD;
             in the liver)&#xD;
&#xD;
          -  Creatinine clearance ≥ 60 mL/min&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No medical problems severe enough to prevent compliance with the study requirements&#xD;
&#xD;
          -  No prior malignancies, except for adequately treated basal cell or squamous cell&#xD;
             carcinoma, carcinoma in situ of the cervix, or other cancer for which the patient has&#xD;
             been disease-free for 5 years&#xD;
&#xD;
          -  No active or uncontrolled infection&#xD;
&#xD;
          -  No pre-existing cardiac disease, including congestive heart failure, arrhythmia&#xD;
             requiring treatment, or myocardial infarction within the past 3 months&#xD;
&#xD;
          -  No pneumonitis&#xD;
&#xD;
          -  No uncontrolled diabetes mellitus (i.e., random blood glucose &gt; 200 mg/dL)&#xD;
&#xD;
          -  No inflammatory bowel disease&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  At least 1 week since prior and no concurrent ketoconazole&#xD;
&#xD;
          -  More than 4 weeks since prior chemotherapy or radiotherapy&#xD;
&#xD;
          -  At least 2 weeks since prior and no concurrent Hypericum perforatum (St. John wort)&#xD;
&#xD;
          -  No prior irinotecan hydrochloride&#xD;
&#xD;
          -  No concurrent investigational antineoplastic therapy or other investigational drugs&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Su Pin Choo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Centre, Singapore</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Cancer Centre - Singapore</name>
      <address>
        <city>Singapore</city>
        <zip>169610</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <study_first_submitted>August 7, 2008</study_first_submitted>
  <study_first_submitted_qc>August 7, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 8, 2008</study_first_posted>
  <last_update_submitted>March 29, 2017</last_update_submitted>
  <last_update_submitted_qc>March 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irinotecan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

